Emergent BioSolutions Inc. reported third quarter 2024 financial results, with total revenues increasing 9% to $293.8 million compared to the prior year. The company achieved a net income of $114.8 million, marking a 144% increase year-over-year, and adjusted EBITDA surged by 432% to $105.3 million.
Despite the overall revenue growth, NARCAN Nasal Spray revenues decreased by 41% in Q4 2024, primarily due to lower sales of over-the-counter NARCAN and Canadian retail sales. Anthrax MCM product revenues also saw a 71% decrease, attributed to the timing of sales for CYFENDUS, Anthrasil, and BioThrax.
Conversely, Smallpox MCM product revenues increased significantly by 565%, driven by higher ACAM2000 sales to non-U.S. customers and the timing of U.S. government purchases of VIGIV CNJ-016. The company raised its full-year 2024 guidance, reflecting confidence in its core products and strategic stabilization actions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.